Entrar/Registro  
INICIO ENGLISH
 
Revista Latinoamericana de Microbiología
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio






>Revistas >Revista Latinoamericana de Microbiología >Año 2005, No. 3-4


Rodríguez-Franco DA, Vázquez-Moreno L, Ramos-Clamont MG
Actividad antimicrobiana de la lactoferrina:Mecanismos y aplicaciones clínicas potenciales
Microbiología 2005; 47 (3-4)

Idioma: Español
Referencias bibliográficas: 119
Paginas: 102-111
Archivo PDF: 180.85 Kb.

[Texto completo - PDF]

RESUMEN

La lactoferrina (Lf) es una glicoproteína multifuncional que presenta la capacidad de unir hierro. Una de las funciones primordiales de la Lf es el transporte de metales. También actúa como proteína de defensa no específica. La Lf se encuentra en diversas secreciones mucosas como la leche, las lágrimas y la saliva. También es un componente abundante de los neutrófilos y puede ser liberada al plasma sanguíneo por la acción de éstos. Las lactoferrinas humana y bovina, despliegan un amplio espectro antimicrobiano, actuando contra bacterias Gram positivas y Gram negativas y contra algunos virus y hongos. Inicialmente se pensó que esta actividad antimicrobiana se debía únicamente a su capacidad de secuestrar hierro. En la actualidad, se sabe que existen diversos mecanismos que contribuyen a la capacidad de esta glicoproteína, para defender a los mamíferos de las infecciones microbianas. Esta revisión presenta un panorama del conocimiento actual acerca de dichos mecanismos y de las aplicaciones clínicas potenciales de la Lf, contra infecciones microbianas.


Palabras clave: Lactoferrina, mecanismos de defensa antibacteriana, antiviral, lactoferricina, aplicaciones clínicas.


REFERENCIAS

  1. Addie D.D., A. Radford, P.S. Yam, & D.J. Taylor. 2003. Cessation of feline calicivirus shedding coincident with resolution of chronic gingivostomatitis in a cat. J. Small Anim. Pract. 44:172-176.

  2. Anderson, B.F., H.M. Baker, G.E. Norris, D.W. Rice, & E.N. Baker. 1989. Structure of human lactoferrin: Crystallographic structure analysis and refinement at 2.8 Å resolution. J. Mol. Biol. 209:711-734.

  3. Arnold, D., A.M. Di Biase, M. Marchetti, A. Pietrantoni, P. Valenti, L. Seganti, & F. Superti. 2002. Antiadenovirus activity of milk proteins: lactoferrin prevents viral infection. Antiviral. Res. 53:153-158.

  4. Baynes, R.D., & W.R. Bezwoda. 1994. Lactoferrin and the inflammatory response. Adv. Exp. Med. Biol. 357:133-141.

  5. Bellamy, W., M. Takase, H. Wakabayashi, K. Kawase, & Tomita, M. 1992a. Antibacterial spectrum of lactoferricin B, a potent bactericidal peptide derived from the N-terminal region of bovine lactoferrin. J. Appl. Bacteriol. 73: 472–479.

  6. Bellamy, W., M. Takase, K. Yamauchi, H. Wakabayashi, K. Kawase, & M. Tomita. 1992b. Identification of the bactericidal domain of lactoferrin. Biochem. Biophys. Acta, 1121:130–136.

  7. Bellamy, W., H. Wakabayashi, M. Takase, K. Kawase, S. Shimamura, & M. Tomita. 1993. Killing of Candida albicans by lactoferricin B, a potent antimicrobial peptide derived from the N-terminal region of bovine lactoferrin. Med. Microbiol. Immunol. 182:97–105.

  8. Bennett, R.M., A.C. Eddie-Quartey, & P.J. Holt. 1973. Lactoferrin: an iron binding protein in synovial fluid. Arthritis Rheum. 16:186–190.

  9. Bernard, K.A., W.B. Klimstra, & R.E. Johnston. 2000. Mutations in the E2 glycoprotein of Venezuelan equine encephalitis virus confer heparan sulfate interaction, low morbidity, and rapid clearance from blood of mice. Virology 276:93-103.

  10. Bezwoda, W.R., & N. Mansoor. 1989. Lactoferrin from human breast milk and from neutrophil granulocytes. Comparative studies of isolation, quantization, characterization and iron binding properties. Biomed. Chromatogr. 3:121–126.

  11. Bhimani, R.S., Y. Vendrov, & P. Furmanski. 1999. Influence of lactoferrin feeding and injection against systemic staphylococcal infections in mice. J. Appl. Microbiol. 86:135–144.

  12. Birkmann, A., K. Mahr, A. Ensser, S. Yaguboglu, F. Titgemeyer, B. Fleckenstein, & F. Neipel. 2001. Cell surface heparan sulfate is a receptor for human herpesvirus 8 and interacts with envelope glycoprotein K8.1. J. Virol. 75:11583-11593.

  13. Boesman-Finkelstein, M., & R.A. Finkelstein. 1985. Antimicrobial effects of human milk: inhibitory activity on enteric pathogens. FEMS Microbiol. Lett. 27:167-174.

  14. Borregaard, N., K. Lollike, L. Kjeldsen, H. Sengelov, L. Bastholm, M. H. Nielsen, & D.F. Bainton. 1993. Human neutrophil granules and secretory vesicles. Eur. J. Haematol. 51:187-198.

  15. Borregaard, N. 2001. Antibiotic molecules: intracellular. Encyclopedia of Life Sciences. Nature Publishing Group. www.els.net.

  16. Brade, L., K. Brandebburg, H.M. Kuhn, S. Kutsomoto, I. Macher, E.T. Rietschel, & H. Brade. 1987. The immunogenecity and antigenicity of lipid A are influenced by its physicochemical state and environment. Infect. Immun. 55:2636-2644.

  17. Brock, J. H. 1980. Lactoferrin in human milk: its role in iron absorption and protection against enteric infection in the newborn infant. Arch. Dis. Child. 55:417-421.

  18. Brock, J. 1995. Lactoferrin: a multifunctional immunoregulatory protein?. Immunol. Today, 16:417–419.

  19. Bullen, J.J. 1981. The significance of iron in infection. Rev. Infect. Dis. 3:1127-1138.

  20. Bullen, J.J., H.J. Rogers, & E. Griffiths. 1978. Role of iron in bacterial infection. Curr. Top. Microbiol. Immunol. 80:1–35.

  21. Byrnes, A.P., & D.E. Griffin. 1998. Binding of Sindbis virus to cell surface heparan sulfate. J. Virol. 72:7349-7356.

  22. Chen, Y., T. Maguire, R.E. Hileman, J.R. Fromm, J.D. Esko, R.J. Linhardt, & R.M Marks. 1997. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat. Med. 3:866-871.

  23. Cohen, J., & M. P. Glauser. 1991. Septic shock: treatment. Lancet 338:736–739.

  24. Cohen, M.S., J. Mao, G.T. Rasmussen, J.S. Serody, & B.E. Britigan. 1992. Interaction of lactoferrin and lipopolysaccharide (LPS): effects on the antioxidant property of lactoferrin and the ability of LPS to prime human neutrophils for enhanced superoxide formation. J. Infect. Dis. 166:1375-1378.

  25. Compton, T., D.M. Nowlin, & N.R. Cooper. 1993. Initiation of human cytomegalovirus infection requires initial interaction with cell surface heparan sulfate. Virology 193:834-841.

  26. Crosa, J.H. 1989. Genetics and molecular biology of siderophore mediated iron transport in bacteria. Microbiol. Rev. 53:517–530.

  27. Danner, R.L., K.A. Joiner, M. Rubin, W.H. Patterson, N. Johnson, K.M. Ayers, & J.E. Parrillo. 1989. Purification, toxicity, and antiendotoxin activity of polymyxin B nonapeptide. Antimicrob. Agents Chemother. 31:230-237.

  28. Debbabi, H., M. Dubarry, M. Rautureau, & D. Tome. 1998. Bovine lactoferrin induces both mucosal and systemic immune response in mice. J. Dairy Res. 65:283–293.

  29. Dial, E.J., L.R. Hall, H. Serna, J.J. Romero, J.G. Fox, & L.M. Lichtenberger. 1998. Antibiotic properties of bovine lactoferrin on Helicobacter pylori. Dig. Dis. Sci. 43:2750-2756.

  30. Dial, E.J., & L.M. Lichtenberger, 2002. Effect of lactoferrin on. Helicobacter felis induced gastritis. Biochem. Cell. Biol. 80:113-117.

  31. Di Mario, F., G. Aragona, N.D. Bo, A. Ingegnoli, G.M. Cavestro, A.M. Moussa, V. Iori, G. Leandro, A. Pilotto, & A. Franze. 2003. Use of Lactoferrin for Helicobacter pylori Eradication: Preliminary Results. J Clin. Gastroenterol. 36(5):396-398

  32. Elass-Rochard, E., D. Legrand, V. Salmon, A. Roseanu, M. Trif, P.S. Tobias, J. Mazurier, & G. Spik. 1998. Lactoferrin inhibits the endotoxin interaction with CD14 by competition with the lipopolysaccharide-binding protein. Infect. Immun. 66:486–491.

  33. Ellison R.T.III. & T.J Giehl. 1991. Killing of Gram-negative bacteria by lactoferrin and lysozyme. J. Clin. Invest. 88:1080-1091.

  34. Esposito, J.J., & J.F. Obljeski. 1976. Enterovirus type 70 virion and intracellular proteins. J. Virol. 18:1160-1162.

  35. Germi, R., J.M. Crance, D. Garin, J. Guimet, H. Lortat-Jacob, R.W. Ruigrok, J.P. Zarski, & E. Drouet. 2002. Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption. Cellular glycosaminoglycans and low-density lipoprotein receptor are involved in hepatitis C virus adsorption. Virology. 292:162-168.

  36. Goodfellow, I.G., A.B. Sioofy, R.M. Powell, & D.J. Evans. 2001. Echoviruses bind heparan sulfate at the cell surface. J. Virol. 75:4918-4921.

  37. Grover, M., O. Giouzeppos, R. D. Schnagl, & J.T. May. 1997. Effect of human milk prostaglandins and lactoferrin on respiratory syncytial virus and rotavirus. Acta Paediatr. 86:315-316.

  38. Harmsen, M.C., P.J. Swart, M.P. Debethune, R. Pauwels, E. Declercq, T.H. The, & D.K.F. Meijer. 1995. Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. J. Infect. Dis. 172:380-388.

  39. Hasegawa, K., W. Motsuchi, S. Tanaka, & S. Dosako. 1994. Inhibition with lactoferrin of in vitro infection with human herpes virus. Jpn. J. Med. Sci. Biol. 47:73-85.

  40. Heil, M.L., A. Albee, J.H. Strauss, & R.J. Kuhn. 2001. An amino acid substitution in the coding region of the E2 glycoprotein adapts Ross River virus to utilize heparan sulfate as an attachment moiety J. Virol. 75:6303-6309.

  41. Hennart, P.F., D.J. Brasseur, J.B. Delogne, M. Desnoeck, M. Dramaix, & C. E. Robyn. 1991. Lysozyme, lactoferrin, and secretory immunoglobulin A content in breast milk: influence of duration of lactation, nutrition status, prolactin status, and parity of mother. Am. J. Clin. Nutr. 53:32-39.

  42. Hilgard, P., & R. Stockert. 2000. Heparan sulfate proteoglycans initiate dengue virus infection of hepatocytes. Hepatology. 32:1069-1077.

  43. Hirai, Y., N. Kawakata, K. Satoh, Y. Ikeda, S. Hisayasu, H. Orimo, & Y. Yoshino. 1990. Concentrations of lactoferrin and iron in human milk at different stages of lactation. J. Nutr. Sci. Vitaminol. Tokyo. 36:531-544.

  44. Hirashima N, E. Orito, & K. Ohba. 2004. A randomized controlled trial of consensus interferon with or without lactoferrin for chronic hepatitis C patients with genotype 1b and high viral load. Hepatol. Res. 29:9-12.

  45. Hutchens, T.W., S.V. Rumball, & B. Lönnerdal. 1994. Lactoferrin: Structure and function. Adv. Exp. Med. Biol. 357:21–32.

  46. Iigo, M., T. Kuhara, Y. Ushida, K. Sekine, M.A. Moore, & H. Tsuda. 1999. Inhibitory effects of bovine lactoferrin on colon carcinoma 26 lung metastasis in mice. Clin. Exp. Metastasis. 17:35–40.

  47. Ishii, K., N. Takamura, T. Ikehara, Y. Nishio, H. Nagai, S. Hara, T Kawafune, Y. Sumino, & W. Yamamuro. 2000. Effect of short-term lactoferrin for patients with chronic hepatitis C. Hepatology. 32:444-448.

  48. Jackson, T., F.M. Ellard, R.A. Ghazaleh, S.M. Brookes, W.E. Blakemore, A.H. Corteyn, D.I. Stuart, J.W. Newman, & A.M. King. 1996. Efficient infection of cells in culture by type O foot-and-mouth disease virus requires binding to cell surface heparan sulfate. J. Virol. 70:5282-5287.

  49. Johansen, B.G. 1960. Isolation of an iron containing red protein from human milk. Acta Chem. Scand. 14:510-512.

  50. Lee, T.H., K. Shimazaki, S.L. Yu, M.S. Nam, S.J. Kim, K.K. Lee, & D.Y. Yu. 1997. Polymorphic sequence of Korean native goat lactoferrin exhibiting greater antibacterial activity. Anim. Genet. 28:367-369.

  51. Kawaguchi, S., T. Hayashi, H. Masano, K. Okuyama, T. Suzuki, & K. Kawase. 1989. Effect of lactoferrin-enriched infant formula on low birth weight infants. Shuusankiigaku. 19:125-130.

  52. Kirkpatrick, C.H., I. Green, R.R. Rich, & A.L. Schade. 1971. Inhibition of growth of Candida albicans by iron-unsaturated lactoferrin: relation to host-defense mechanisms in chronic mucocutaneous candidiasis. J. Infect. Dis. 124:539-544.

  53. Klimstra, W.B., H.W. Heidner, & R.E. Johnston. 1999. Adaptation of Sindbis virus to BHK cells selects for use of heparan sulfate as an attachment receptor. J. Virol. 73:6299-6306.

  54. Kuipers, M.E., H.G. de Vries, M.C. Eikelboom, D.K.F. Meijer, & P.J. Swart. 1999. Synergistic fungistatic effects of lactoferrin in combination with antifungal drugs against clinical Candida isolates. Antimicr. Agents Chemother. 43:2635-2641.

  55. Kuhara, T., M. Iigo, T. Ito, Y Ushida, K. Sekine, N. Terada, H. Okamura, & H. Tsuda. 2001. Orally administered lactoferrina exerts an antimetastatic effect and enhances production of IL-18 in the intestinal epthielium. Nutr. Cancer. 38:192–199.

  56. Levay, P.F., & M. Viljoen. 1995. Lactoferrin: a general review. Acta Haematol. 80:252-267.

  57. Lewis, L.A., K. Rohde, M. Gipson, B. Behrens, E. Gray, S.I.Toth, B.A. Roe, & D.W. Dyer. 1998. Identification and molecular analysis of LbpBa, which encodes the two-component meningococcal lactoferrin receptor. Infect. Immun. 66:3017–3023.

  58. Lönnerdal, B., & S. Iyer. 1995. Lactoferrin: molecular structure and biological function. Annu. Rev. Nutr. 15:93-110.

  59. Majerle, A., J. Kidric, & R. Jerala. 2003. Enhancement of antibacterial and lipopolysaccharide binding activities of a human lactoferrin peptide fragment by the addition of acyl chain. J, Antimicrob. Chemother. 51:1159-1165.

  60. Marchetti, M., F. Superti, M.G. Ammendolia, P. Rossi, P. Valenti, & L. Seganti. 1999. Poliovirus type 1 infection by iron-, manganese- and zinc-saturated lactoferrin. Med. Microbiol. Immunol. 187:199-204.

  61. Marra, M.N., C.G. Wilde, J.E. Griffith, J.L. Snable, & R.W. Scott. 1990. Bactericidal/permeability increasing protein has endotoxin-neutralizing activity. J. Immunol. 144:662-666.

  62. Masson, P.L., & J.F. Heremans. 1966. Studies on lactoferrin, the iron binding protein of secretions. Prot. Biol. Fluids. 14:115-124.

  63. Meijer D.K.F., R.P.G. van Heeswijk, P.J. Swart, L. Beljaars, J.G. Huisman, A. Koenderman, T.H. The, M.C. Harmsen, R. Floris, J.J.M. van den Berg, C. Smit, H. Bakker, B.W.A. van der Strate, M.E. Kuipers, R.W. Jansen, G. Molema, & B. Berkhout. 2001. Charge-modified plasma and milk proteins that interfere with HIV and CMV/target cell binding and fusion. Recent Dev. Antivir. Res. 1:81-115.

  64. Miyazawa, K., C. Mantel, L. Lu, D.C. Morrison, & H.E. Broxmeyer. 1991. Lactoferrin-lipopolysaccharide interactions. Effect on lactoferrin binding to monocyte/macrophage-differentiated HL-60 cells. J. Immunol. 146:723-729.

  65. Morrison, D. C. 1998. Antibiotic-mediated release of endotoxin and the pathogenesis of Gram-negative sepsis. Prog. Clin Biol. Res. 397:199–207.

  66. Murphy, M.E., H. Kariwa, T. Mizutani, K. Yoshimatsu, J. Arikawa, & I. Takashima. 2000. In vitro antiviral activity of lactoferrin and ribavirin upon hantavirus. Arch. Virol. 145:1571-1582.

  67. Nakajima, M., H. Iwamoto, T. Shirasawa, H. Miyauchi, Z. Takatsu & N. Yamazaki. 1999. Oral administration of lactoferrin enhances the production of IFN-g and IL-10 in spleen cells cultured with concanavalin A or lipopolysaccharide. Biomed. Res. 20:27–33.

  68. Nemet, K., & I. Simonovits. 1985. The biological role of lactoferrin. Haematologia, 18:3–12.

  69. Nibbering, P.H., E. Ravensbergen, M.M. Welling, L.A. Van Berkel, P.H. C. Van Berkel, E. K. J. Pauwels, & J. H. Nuijens. 2001. Human lactoferrin and peptides derived from its N terminus are highly effective against infections with antibiotic-resistant bacteria. Infect. Immun. 69:1469-1476.

  70. Pakkanen, R., & J. Alto. 1997. Review paper: Growth factors and antimicrobial factors of bovine colostrums. Int. Dairy J. 7:285-297.

  71. Patel, M., M. Yanagishita, G. Roderiquez, D.C. Bouhabib, T. Oravecz, V.C. Hascall, & M.A. Norcross. 1993. Cell-surface heparan sulfate proteoglycan mediates HIV-1 infection of T-cell lines. Aids Res. Hum. Retrov. 9:167-174.

  72. Paterson, A.A., S.W. Fesik, & E.J. McGroarty. 1987. Decreased binding of antibiotics to lipopolysaccharide from polymyxin-resistant strains of Escherichia coli and Salmonella typhimurium. Antimicrob. Agents Chemother. 31: 230-237.

  73. Pietrantoni, A., A.M. Di Biase, A. Tinari, M. Marchetti, P. Valenti, L. Seganti & F. Superti. 2003. Bovine lactoferrin inhibits adenovirus infection by interacting with viral structural polypeptides. Antimicrob. Agents Chemother. 47:2688–2691.

  74. Puddu, P., P. Borghi, S. Gessani, P. Valenti, F. Belardelli, & L. Seganti. 1998. Antiviral effect of bovine lactoferrin saturated with metal ions on early steps of human immunodeficiency virus type 1 infection. Int. J. Biochem. Cell B. 30: 1055-1063.

  75. Putman, M., L. A. Koole, H. W. van Veen, & W. N. Konings. 1999. The secondary multidrug transporter LmrP contains multiple drug interaction sites. Biochemistry 38:13900-13905.

  76. Recio, I., & S. Visser. 2000. Antibacterial and binding characteristics of bovine, ovine and caprine lactoferrins: A comparative study Int. Dairy J. 10:597-605.

  77. Reinard, P. 1986. Bacteriostasis of E. coli by bovine lactoferrin, transferrin and immunoglobulins (IgG1, IgG2, IgM) acting alone or in combination. Vet. Microbiol. 11:103-115.

  78. Reiter, B. 1983. The biological significance of lactoferrin. Int. J. Tissue React. 5:87-96.

  79. Reiter, B. 1985. The biological significance of the non-immunoglobulin protective proteins in milk. Dev. Dairy Chem. 3:281-336.

  80. Rietschel, E.T., T. Kirikae, F.U. Schade, U. Mamat, G. Schmidt, & H. Loppnow. 1994. Bacterial endotoxin: molecular relationships of structure to activity and function. FASEB J. 8:217–25.

  81. Roberts, A.K., R. Chierici, G. Sawatzki, M.J. Hill, S. Volpato, & V. Vigi. 1992. Supplementation of an adapted formula with bovine lactoferrin: 1. Effect on the infant fecal flora. Acta Paediatr. 81:119-124.

  82. Rogers, H.J., & C. Synge. 1978. Bacteriostatic effect of human milk on E. coli: The role of IgA. Immunology. 34:19-28.

  83. Roque, W.J., S.W. Fesik, A. Haug, & E.J. McGroarty. 1987. Polycation binding to isolates lipopolysaccharide from antibiotic-hypersusceptible mutants strains of Escherichia coli. Antimicrob Agents Chemother. 32:308-313.

  84. Samson, R.R., C. Mirtle, & D.B.L. McClelland. 1979. Secretory IgA does not enhance the bacteriostatic effect of iron-binding or vitamin B12-binding protein in human colostrum. Immunology. 38: 367-373.

  85. Sato, R., O. Inanami, Y. Tanaka, M. Takase, & Y. Naito. 1996. Oral administration of bovine lactoferrin for treatment of intractable stomatitis in feline immunodeficiency virus (FIV)-positive and FIV-negative cats. Am J. Vet. Res. 57:1443-1446.

  86. Schryvers, A.B., R. Bonnah, R.H. Yu, H. Wong, & M. Retzer. 1998. Bacterial lactoferrin receptors. Adv. Exp. Med. Biol. 443:123–133.

  87. Sekine, K., Y. Ushida, T. Kuhara, M. Iigo, H. Baba-Toriyama & M.A Moore. 1997. Inhibition of initiation and early stage development of aberrant crypt foci and enhanced natural killer activity in male rats administered bovine lactoferrin concomitantly with azoxymethane. Cancer Lett. 121:211–216.

  88. Shukla, D., & P.G. Spear. 2001. Herpesviruses and heparan sulfate: an intimate relationship in aid of viral entry J. Clin. Invest. 108:503-510.

  89. Sorensen, M., & S.P.L. Sorensen. 1939. The protein in whey. Trav. Lab. Carlsberg. 23:55-99.

  90. Stephens, S., J.M. Dolby, J. Montreuil, & G Spik. 1980. Differences in inhibition of the growth of commensal and enteropathogenic strains of E. coli by lactoferrin and sIgA isolated from human milk. Immunology. 41:597-603.

  91. Stokes, D. C., J. L. Shenep, M. Fishman, W. K. Hildner, G. K. Bysani, & K. Rufus. 1989. Polymyxin B prevents lipopolysaccharide-induced release of tumor necrosis factor-alpha from alveolar macrophages. J. Infect. Dis. 160:52–57.

  92. Summerford, C., & R.J. Samulski. 1998. Membrane-associated heparan sulfate. J. Virol. 72:1438-1445.

  93. Superti, F., M. G. Ammendolia, P. Valenti, & L. Seganti. 1997. Antirotaviral activity of milk proteins: lactoferrin prevents rotavirus infection in the enterocyte-like cell line HT-29. Med. Microbiol. Immunol. 186:83-91.

  94. Swart, P.J., E.M. Kuipers, C. Smit, B.W.A. Van Der Strate, M.C. Harmsen, & D.K. Meijer. 1998. Antiviral activity of lactoferrin. Adv. Exp. Med. Biol. 443:205-213.

  95. Swart, P.J., M.C. Harmsen, M.I. Kuipers, A.A. Van Dijk, B.W.A. van der Strate, P.H.C. Van Berkel, J.H. Nuijens, C. Smit, M. Witvrouw, E. De Clercq, M.P. De Bethune, R. Pauwels, & D.K.F. Meijer. 1999. Charge modification of plasma and milk proteins in antiviral active compounds. J. Pept. Sci. 5:563-576.

  96. Swart, P.J., M.E. Kuipers, C. Smit, R. Pauwels, M.P. DeBethune, E. DeCleroq, D.K. Meijer, & J.G. Huisman, J.G. 1996. Antiviral effects of milk proteins: acylation results in polyanionic compounds with portent activity against human immunodeficiency virus types 1 and 2 in vitro. Aids Res. Human Retroviruses 12:769-775.

  97. Tanaka, K., M. Ikeda, A. Nozaki, N. Kato, H. Tsuda, S. Saito, & H Sekihara. 1999. Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C: a pilot study. Jpn. J. Cancer Res. 90:367–371.

  98. Tomita, M., M. Takase, W. Bellamy, & S. Shimamura. 1994. A review: the active peptide of lactoferrin. Acta Paediatr. Jpn. 36:585–591.

  99. Tomita, M., H. Wakabayashi, K. Yamauchi, S. Teraguchi, & H Hayasawa. 2002. Bovine lactoferrin and lactoferricin derived from milk production and applications. Biochem. Cell Biol. 80:109-112.

  100. Troost, F.J., W.H. M. Saris, & R-J.M. Brummer. 2002. Orally ingested human lactoferrin is digested and secreted in the upper gastrointestinal tract in vivo in women with ileostomies. J. Nutr. 78:2597-2600.

  101. Trumpler, U.P., W. Straub, & A. Rosenmund. 1989. Antibacterial prophylaxis with lactoferrin in neutropaenic patients. Eur. J. Clin. Microbiol. Infect. Dis. 8:310-318.

  102. Trybala, E., A. Roth, M. Johansson, J.A. Liljeqvist, E. Rekabdar, O. Larm, & T. Bergstrom. 2002. Herpes simplex virus type 1 glycoprotein C is necessary for efficient infection of chondroitin sulfate-expressing gro2C cells. Virology: 302:413-419.

  103. Valenti, P., M. Marchetti, F. Superti, M.G. Amendolia, P. Puddu, S. Gessani, P. Borghi, F. Belardelli, G. Antonini, & L. Seganti. 1998. Antiviral activity of lactoferrin. Adv. Exp. Med. Biol. 443:199–203.

  104. Van Berkel, P.H., M.E. Geerts, H.A. van Veen, M. Mericskay, H.A. de Boer, & J.H. Nuijens. 1997. N-terminal stretch arg2, arg3, arg4 and arg5 of human lactoferrin is essential for binding to heparin, bacterial lipopolysaccharide, human lysozyme and DNA. Biochem. J. 328:145–151.

  105. Van Berkel, P. H.C., M.M. Welling, M. Geerts, H.A. van Veen, B. Ravensbergen, M. Salaheddine1, E.K.J. Pauwels, F. Pieper, J.H. Nuijens, & P. H. Nibbering. 2002. Large scale production of recombinant human lactoferrin in the milk of transgenic cows. Nature Biotech. 20:484-487.

  106. Van Hooijdonk, A., K. D. Kussendrager, & J Steijns. M. 2000. In vivo antimicrobial and antiviral activity of components in bovine milk and colostrum involved in non-specific defense. Br. J. Nutr. 84:127-134.

  107. Van der Strate, B.W.A., L. Beljaars, G. Molema, M.C. Harmsen, & D.K.F. Meijer. 2001. Antiviral activities of lactoferrin. Antivir. Res. 52:225-239.

  108. Van der Strate, B.W.A., M.C. Harmsen, T.H. The, H.G. Sprenger, H. de Vries, M.C. Eikelboom, M.E. Kuipers, D.K.F. Meijer, & P.J. Swart. 2000. Plasma Lactoferrin levels are decreased in end-stage AIDS-patients. Viral Immunol. 12:197-203.

  109. Vorland, L. H. 1999. Lactoferrin: a multifunctional glycoprotein. Apmis 107:971-981.

  110. Waarts, B.L., O. Aneke, J.M. Smit, K. Kimata, R. Bittman, D Meijer & J. Wilschut. 2004. Antiviral activity of human lactoferrin: Inhibition of alphavirus interaction with heparan sulfate. pp 108-120 In B.L Waarts (Eds). Cell entry mechanisms of alphavirus editor. Groningen University. The Netherlands.

  111. Wakabayashi, H., S. Abe, T. Okutomi, S. Tansho, K. Kawase, & H. Yamaguchi. 1996. Cooperative anti-Candida effects of lactoferrin or its peptides in combination with azole antifungal agents. Microbiol. Immunol. 40:821-825.

  112. Wakabayashi H., K. Uchida, K. Yamauchi, S. Teraguchi, H. Hayasawa, & H. Yamaguchi. 2000. Lactoferrin given in food facilitates dermatophytosis cure in guinea pig models. J. Antimicr. Chem. 46:595-602.

  113. Wang, W.P.,M. Iigo, J. Sato, K. Kazuhiro, I. Adachi, & H. Tsuda, H. 2000. Activation of intestinal mucosal immunity in tumor-bearing mice by lactoferrin. Jpn. J. Cancer Res. 91:1022–1027.

  114. Ward, P.P., S. Uribe-Luna, & O. Conneely. 2002. Lactoferrin and host defense. Biochem. Cell Biol. 80:95-102.

  115. Yamauchi, K., M. Tomita, T.J. Giehl & R.T. Ellison III. 1993. Antibacterial activity of lactoferrin and a pepsin-derived lactoferrin peptide fragment. Infect. Immun. 61:719-728.

  116. Yi, M. Y., S. Kaneko, D. Y. Yu, & S. Murakami. 1997. Hepatitis C virus envelope proteins bind lactoferrin. J. Virol. 71:5997-6002.

  117. Yoshida, S., Z. Wei, Y. Shinmura, & N. Fukunaga. 2000. Separation of lactoferrin-a and lactoferrin-b from bovine colostrum. J. Dairy Sci. 83:2211-2215.

  118. Zagulski T, P. Lipinski , A. Zagulska, & Z. Jarzabek. 1998. Antibacterial system generated by lactoferrin in mice in vivo is primarily a killing system. Int J. Exp. Pathol. 79:117-123.

  119. Zimecki, M., A. Wlaszczyk, P. Cheneau, A-S. Brunel, J. Mazurier, & G. Spik. 1998. Immunoregulatory effects of a nutritional preparation containing bovine lactoferrin taken orally by healthy individuals. Arch. Immun. Ther. Exp. 46:231–40.



>Revistas >Revista Latinoamericana de Microbiología >Año2005, No. 3-4
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019